Alisertib

Small molecule

Also known as MLN8237

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Other / comorbidity
NCT01482962 · Millennium Pharmaceuticals, Inc.
2012-06-11 – 2017-12-18 · Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
What this study did
Phase 2 (22)
Small Cell Lung Cancer
NCT07465757 · Puma Biotechnology, Inc.
2026-09-17 – 2028-09-30 · Small Cell Lung Cancer ( SCLC )
What this study did
Other / comorbidity
NCT06369285 · Puma Biotechnology, Inc.
2024-11-19 – 2029-06-30 · Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
What this study did
NCT07706179 · University of Wisconsin, Madison
2026-11 – 2028-09 · HR+/HER2+ Breast Cancer, Metastatic Breast Cancer
What this study did
NCT02114229 · St. Jude Children's Research Hospital
2014-05-14 – 2027-09 · Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor
What this study did
NCT02860000 · Mayo Clinic
2017-07-06 – 2025-02-14 · Estrogen Receptor Status, HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
What this study did
NCT02187991 · US Oncology Research
2015-02-12 – 2024-08-01 · Breast Cancer, Breast Carcinoma, Breast Tumors, Malignant Neoplasm of Breast
What this study did
NCT02293005 · M.D. Anderson Cancer Center
2015-05-20 – 2021-07-06 · Lung Cancer, Mesothelioma
What this study did
NCT01154816 · Children's Oncology Group
2011-02 – 2019-06-30 · Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Kidney Neoplasm, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma
What this study did
NCT02560025 · Massachusetts General Hospital
2015-12 – 2018-12 · Acute Myeloid Leukemia
What this study did
NCT01799278 · Weill Medical College of Cornell University
2013-02 – 2017-08 · Small Cell Prostate Cancer, Neuroendocrine Prostate Cancer, Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers
What this study did
NCT01091428 · Millennium Pharmaceuticals, Inc.
2010-04-16 – 2017-07-19 · Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Cancer, Breast Carcinoma
What this study did
NCT01812005 · Ohio State University Comprehensive Cancer Center
2013-05-21 – 2017-04-20 · Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
What this study did
NCT01637961 · National Cancer Institute (NCI)
2012-08 – 2017-02-11 · Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma
What this study did
NCT02109328 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
2014-08-28 – 2016-10-12 · Bladder Cancer, Transitional Cell Carcinoma
What this study did
NCT01653028 · National Cancer Institute (NCI)
2012-08-22 – 2015-08-02 · Myxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Leiomyosarcoma, Recurrent Liposarcoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7
What this study did
NCT01316692 · Vanderbilt-Ingram Cancer Center
2011-10 – 2015-08 · Recurrent Melanoma, Stage IIIc Melanoma, Stage IV Melanoma
What this study did
NCT01466881 · National Cancer Institute (NCI)
2011-10 – 2015-03 · Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma
What this study did
NCT00807495 · Millennium Pharmaceuticals, Inc.
2009-02-10 – 2013-02-13 · Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma, T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma, Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component
What this study did
NCT00830518 · Millennium Pharmaceuticals, Inc.
2009-02-10 – 2011-07-04 · Acute Myelogenous Leukemia, High-Grade Myelodysplastic Syndrome
What this study did
NCT00853307 · Millennium Pharmaceuticals, Inc.
2009-03-23 – 2011-01-27 · Ovarian Carcinoma
What this study did
Phase 1/2 (7)
Small Cell Lung Cancer
NCT01045421 · Millennium Pharmaceuticals, Inc.
2010-02 – 2014-04 · Advanced Nonhematological Malignancies, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastroesophageal Adenocarcinoma
What this study did
Other / comorbidity
NCT04555837 · M.D. Anderson Cancer Center
2020-09-15 – 2025-04-08 · Head and Neck Squamous Cell Carcinoma, Malignant Solid Neoplasm
What this study did
NCT01601535 · New Approaches to Neuroblastoma Therapy Consortium
2012-05 – 2018-07-25 · Neuroblastoma
What this study did
NCT01471964 · Fox Chase Cancer Center
2011-10-20 – 2018-04-10 · Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Recurrent
What this study did
NCT01397825 · Millennium Pharmaceuticals, Inc.
2011-08-09 – 2016-10-05 · Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma
What this study did
NCT01848067 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2013-08-14 – 2016-06-23 · Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
What this study did
NCT01034553 · Mayo Clinic
2010-02 – 2014-11 · Refractory Multiple Myeloma
What this study did
Phase 1 (34)
Small Cell Lung Cancer
NCT02367352 · Millennium Pharmaceuticals, Inc.
2015-03-19 – 2017-05-23 · Advanced Solid Tumors, Ovarian Cancer, Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT01695941 · National Cancer Institute (NCI)
2012-08-31 – 2027-03-03 · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma
What this study did
NCT04085315 · Collin Blakely
2019-11-12 – 2025-10-20 · Lung Cancer Metastatic, EGFR Gene Mutation
What this study did
NCT04479306 · M.D. Anderson Cancer Center
2020-06-18 – 2023-07-27 · Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT02812056 · M.D. Anderson Cancer Center
2016-09 – 2021-09 · Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Malignant Neoplasms of Male Genital Organs
What this study did
NCT02719691 · University of Colorado, Denver
2016-05-13 – 2020-03-18 · Metastatic Breast Cancer, Solid Tumors
What this study did
NCT02186509 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2015-01-30 – 2018-12-31 · Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymal Giant Cell Astrocytoma, Recurrent Adult Brain Tumor
What this study did
NCT01897012 · National Cancer Institute (NCI)
2013-07-17 – 2018-11-30 · MYC Positive, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
What this study did
NCT02219789 · Mayo Clinic
2014-12-05 – 2018-10-01 · Estrogen Receptor Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
What this study did
NCT02319018 · National Cancer Institute (NCI)
2015-08-27 – 2018-09-29 · Malignant Digestive System Neoplasm
What this study did
NCT02780011 · Eric Bernicker, MD
2015-12 – 2018-09 · CD30-positive Lymphoma, CD30-positive Solid Tumor
What this study did
NCT02327169 · Millennium Pharmaceuticals, Inc.
2015-01-14 – 2018-07-02 · Advanced Nonhematologic Malignancies
What this study did
NCT01567709 · National Cancer Institute (NCI)
2012-04-16 – 2018-03-29 · Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Chronic Lymphocytic Leukemia, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Hepatosplenic T-Cell Lymphoma, Intraocular Lymphoma, Lymphomatous Involvement of Non-Cutaneous Extranodal Site, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Primary Cutaneous B-Cell Non-Hodgkin Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, T-Cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenstrom Macroglobulinemia
What this study did
NCT02700022 · UNC Lineberger Comprehensive Cancer Center
2016-10 – 2017-08-18 · Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma
What this study did
NCT01677559 · Washington University School of Medicine
2013-05-07 – 2017-08-11 · Adenocarcinoma, Pancreatic Neoplasms
What this study did
NCT02551055 · Millennium Pharmaceuticals, Inc.
2015-10-15 – 2017-02-17 · Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma
What this study did
NCT01924260 · Edward Kim
2013-08-09 – 2017-02-08 · Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT01898078 · Millennium Pharmaceuticals, Inc.
2013-07-16 – 2017-01-24 · Advanced Solid Tumors, Lymphoma
What this study did
NCT01094288 · Millennium Pharmaceuticals, Inc.
2010-08-17 – 2017-01-04 · Advanced Solid Tumors, Adenocarcinoma of the Prostate
What this study did
NCT01779843 · Massachusetts General Hospital
2013-04 – 2016-11 · Acute Myelogenous Leukemia
What this study did
NCT02259010 · Millennium Pharmaceuticals, Inc.
2014-10-22 – 2016-10-21 · Advanced Solid Tumors, Relapsed/Refractory Lymphoma
What this study did
NCT00697346 · Millennium Pharmaceuticals, Inc.
2008-07-11 – 2016-10-19 · B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, B-cell Mantle Cell Lymphoma, B-cell Small Lymphocytic Lymphoma, B-Cell Chronic Lymphocytic Leukemia, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Enteropathy Associated T-cell Lymphoma, NK Lymphoma
What this study did
NCT01923337 · University of California, Davis
2013-08 – 2016-10-17 · Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT01844583 · Millennium Pharmaceuticals, Inc.
2013-06-25 – 2016-09-06 · Solid Tumors, Lymphoma
What this study did
NCT01639911 · University of Illinois at Chicago
2013-08-14 – 2016-07-28 · Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm of Gastrointestinal Tract, Genitourinary Neoplasms Malignancy and Gender Unspecified, Head and Neck Neoplasms, Melanoma, Malignant Neoplasm of Thorax
What this study did
NCT02214147 · Millennium Pharmaceuticals, Inc.
2014-08-21 – 2016-07-18 · Advanced Solid Tumors, Relapsed/Refractory Lymphoma
What this study did
NCT01613261 · Millennium Pharmaceuticals, Inc.
2013-08 – 2015-11 · Advanced Nonhematologic Malignancies
What this study did
NCT01540682 · Abramson Cancer Center at Penn Medicine
2012-02 – 2015-11 · Head and Neck Cancer
What this study did
NCT00962091 · Millennium Pharmaceuticals, Inc.
2009-09-25 – 2014-07-01 · Advanced Solid Tumors
What this study did
NCT01512758 · Millennium Pharmaceuticals, Inc.
2012-02-06 – 2013-10-08 · Advanced Solid Tumors, Lymphomas
What this study did
NCT01714947 · Millennium Pharmaceuticals, Inc.
2013-01-24 – 2013-06-14 · Advanced Solid Tumors, Lymphoma
What this study did
NCT02444884 · Children's Oncology Group
2008-09 – 2011-12 · Unspecified Childhood Solid Tumor, Excluding CNS, Neuroblastoma
What this study did
NCT00651664 · Millennium Pharmaceuticals, Inc.
2007-10-22 – 2011-04-05 · Advanced Malignancies
What this study did
NCT00500903 · Millennium Pharmaceuticals, Inc.
2007-05-15 – 2011-02-23 · Advanced Malignancies
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT02530619 · Northwestern University
2015-10-09 – 2022-05 · Acute Megakaryoblastic Leukemia, Myelofibrosis, Primary Myelofibrosis
What this study did

Competitive landscape

Other Aurora kinase A (AURKA) drugs

VIC-1911. Compare all 2 Aurora kinase A (AURKA) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Small Cell Lung Cancer: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Alisertib: this drugPhase 2Small moleculeAurora kinase A (AURKA)not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
LurbinectedinApprovedSmall moleculeAlkylating DrugPartial signalNo reviewed efficacy summary in this indication
TarlatamabApprovedMultispecific antibodyDLL3 and CD3Partial signal
NCT06211036: Primary endpoint, overall survival: met at a pre-specified interim analysis (Amgen, 2026-09-08).
NCT05740566: Overall survival: median 13.6 months (95% CI 11.1 to not reached) vs 8.3 months (95% CI 7.0 to 10.2) on chemotherapy; stratified hazard ratio for death 0.60 (DeLLphi-304, NEJM 2025).
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
ABBV-706Phase 3Antibody–drug conjugateSEZ6not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
AL8326Phase 3Small moleculeAurora B / FGFR / VEGFR (multi-kinase)Weak signal
NCT04890795: ORR 20% (6/30, 4 confirmed responses); median PFS 3.65 months; median OS 10.42 months in 30 evaluable ≥3rd-line SCLC patients (data cutoff Nov 30, 2022)
AtigotatugPhase 3Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
GocatamigPhase 3Multispecific antibody—not yet gradedNo reviewed efficacy summary in this indication
Ifinatamab DeruxtecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
ObrixtamigPhase 3Multispecific antibodyDLL3 (Delta-like ligand 3) x CD3not yet gradedNo reviewed efficacy summary in this indication
PumitamigPhase 3Multispecific antibodyPD-L1 and VEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Risvutatug RezetecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
SerplulimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
TislelizumabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
BMS-986525Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
DJI136Phase 1/2Cell therapyDLL3not yet gradedNo reviewed efficacy summary in this indication
Quaratusugene Ozeplasmid (Reqorsa)Phase 1/2Gene therapy / editingTUSC2 (tumor suppressor gene replacement)not yet gradedNo reviewed efficacy summary in this indication
VIC-1911
Phase 1(overall)
Small moleculeAurora kinase A (AURKA)
Weak signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Alisertib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
October 2027 (1)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-10-30 · NCT06095505 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast CancerRecruiting
Est. primary completion 2027-12-30 · NCT06369285 · CT.gov ↗
What to watch
2028 (2)
March 2028 (1)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2028-03-31 · NCT07465757 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2HR+/HER2+ Breast Cancer, Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-09 · NCT07706179 · CT.gov ↗
What to watch

See the full readout calendar ↗